Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Marco Montillo et al.|New England Journal of Medicine|2014Cited by 1.6k
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D. Shanafelt, Martin S. Tallman, Xin V. Wang et al.|New England Journal of Medicine|2019Cited by 735
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, Peter Hillmen et al.|Journal of Clinical Oncology|2021Cited by 630
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaLaura Z. Rassenti, Thomas J. Kipps, Sonia Jain et al.|Blood|2008Cited by 320
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaNeil E. Kay, John C. Byrd|Blood|2006Cited by 293